Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Revumenib citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Revumenib citrate overview

Revumenib Citrate (Revuforj) is an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Revuforj is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. 
Revumenib citrate (SNDX-5613) is under development for the treatment of genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene such as relapsed and refractory acute lymphoblastic leukemia, relapsed and refractory acute myelobalstic leukemia and unresectable metastatic microsatellite stable colorectal cancer. It is administered through oral route in the form of capsules. The drug candidate acts by targeting interaction of menin with the mixed lineage leukemia (MLL) protein.

Syndax Pharmaceuticals overview

Syndax Pharmaceuticals (Syndax) is a biopharmaceutical company that discovers, develops and commercializes therapies for multiple cancer indications. The company’s pipeline products include AUGMENT-101-2A for the treatment of R/R KMT2Ar acute lymphoblastic leukemia (ALL), AUGMENT-101-2B treats R/R KMT2Am acute myeloid eukemia (AML); AUGMENT-101-2C for R/R NPM1m Acute Myeloid Leukemia (AML); AUGMENT-102 targets R/R KMT2Ar and NPM1m acute leukemias; BEAT-AML for the treatment of Frontline KMT2Ar and NPM1m Acute Myeloid Leukemia (AML); INTERCEPT for MRD- progression in KMT2Ar and NPM1m acute myeloid leukemia (AML); Colorectal Cancer targets newly diagnosed NPM1m or KMT2Ar acute leukemias; AGAVE-201 treats chronic graft-versus-host disease (GVHD); Idiopathic Pulmonary Fibrosis for idiopathic pulmonary fibrosis. Syndax is headquartered in Waltham, Massachusetts, the US.

For a complete picture of Revumenib citrate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.